AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26990515 — intervention group
Group type: EXPERIMENTAL
Intervention: Linox(smart) ICD leads
Number of subjects: 3840
Study 26990515 — intervention group
Group type: COMPARATOR
Intervention: Linox and Linox(smart) ICD leads
Number of subjects: 3840
Study 26990620 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies measured every trimester and postpartum; IgG aPL levels significantly lower during the second and third trimesters compared to initial screening.
Number of subjects: 152
Study 26990620 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies measured every trimester and postpartum; IgM aPL titers were negative in the majority of patients and decreased modestly during pregnancy.
Number of subjects: 152
Study 26990620 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies measured every trimester and postpartum; changes in aPL levels or aPL status.
Number of subjects: 152
Study 26990620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LAC) presence.
Number of subjects: 152
Study 26990995 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable therapy (specifics not provided)
Number of subjects: 2788
Study 26990995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain measurement
Number of subjects: 2788
Study 26990995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue measurement
Number of subjects: 2788
Study 26990995 — intervention group
Group type: EXPERIMENTAL
Intervention: Function measurement
Number of subjects: 2788
Study 26991245 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), n=23
Number of subjects: 70
Study 26991245 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA), n=22
Number of subjects: 70
Study 26991245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ), n=25
Number of subjects: 70
Study 26991245 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 70
Study 26991631 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frailty scores
Number of subjects: 445
Study 26991631 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher comorbidity scores
Number of subjects: 445
Study 26991631 — intervention group
Group type: EXPERIMENTAL
Intervention: Any disability
Number of subjects: 445
Study 26991631 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired grip strength
Number of subjects: 445
Study 26991631 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed chair stand tests
Number of subjects: 445
Study 26991631 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of frailty scores
Number of subjects: 445
Study 26991631 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of comorbidity scores
Number of subjects: 445
Study 26991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 100 mg once daily (3 weeks on/1 week off)
Number of subjects: 12
Study 26991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg once daily (3 weeks on/1 week off)
Number of subjects: 12
Study 26991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg plus letrozole 2.5 mg
Number of subjects: 12
Study 26991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 100 mg
Number of subjects: 12
Study 26991902 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (60-180 μg)
Number of subjects: 2630
Study 26992304 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency segmental thermal ablation of refluxing GSVs
Number of subjects: 93
Study 26992693 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital epithelial disruptions
Number of subjects: 1485
Study 26992693 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal vaginal discharge
Number of subjects: 1485
Study 26992693 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital signs and symptoms
Number of subjects: 1485
Study 26992693 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital ulcers/sores
Number of subjects: 1485
Study 26993068 — intervention group
Group type: EXPERIMENTAL
Intervention: scFEM depot
Number of subjects: 25
Study 26993068 — intervention group
Group type: COMPARATOR
Intervention: scABD depot
Number of subjects: 25
Study 26993068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scABD and scFEM depots
Number of subjects: 25
Study 26993070 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoglycemia (2.8 mmol/L) during a hyperinsulinemic euglycemic-hypoglycemic glucose clamp after an overnight fast.
Number of subjects: 21
Study 26993070 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n = 7) during acute hypoglycemia (2.8 mmol/L).
Number of subjects: 21
Study 26993070 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal awareness of hypoglycemia (NAH) during acute hypoglycemia (2.8 mmol/L).
Number of subjects: 21
Study 26993071 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based method to estimate hepatic and extrahepatic insulin clearance
Number of subjects: 100
Study 26993131 — intervention group
Group type: EXPERIMENTAL
Intervention: dHER2 immunotherapeutic (20, 100, 500 µg) combined with AS15
Number of subjects: 61
Study 26993131 — intervention group
Group type: EXPERIMENTAL
Intervention: dHER2 immunotherapeutic (500 µg) with the most intense immunization schedule
Number of subjects: 61
Study 26993266 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase β (1 mg/kg every 2 weeks)
Number of subjects: 1044
Study 26993370 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-lung bronchoalveolar lavage (BAL)
Number of subjects: 79
Study 26993370 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-lung bronchoalveolar lavage (BAL)
Number of subjects: 79
Study 26993370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral BAL cultures
Number of subjects: 79
Study 26993370 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated prescribing based on right or left cultures
Number of subjects: 79
Study 26993370 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a radiographic infiltrate in the sampling area
Number of subjects: 79
Study 26993674 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous cyanoacrylate (CA) embolization
Number of subjects: 70
Study 26993758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib
Number of subjects: 52
Study 26993869 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation at a current twice their motor threshold, at 1 Hz, for 5 minutes.
Number of subjects: 12
Study 26993869 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonstimulated side)
Number of subjects: 12
Study 26994130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality risk acceptance during AVR
Number of subjects: 439
Study 26994130 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of prohibitive risk willingness (>50%)
Number of subjects: 439
Study 26994130 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing score on EuroQol-Visual Analog Scale
Number of subjects: 439
Study 26994231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 107
Study 26994231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with decreased pain sensation
Number of subjects: 107
Study 26994231 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients requiring more than 0.5 mA to evoke a motor response
Number of subjects: 107
Study 26994231 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowed ulnar nerve conduction velocity
Number of subjects: 107
Study 26994848 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 4
Study 26995233 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 1563
Study 26995365 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular device interventions in symptomatic lower extremity PAD
Number of subjects: 1200
Study 26995690 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital single-operator cholangiopancreatoscopy (SOC)
Number of subjects: 105
Study 26998310 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing interest among parents
Number of subjects: 320
Study 26998310 — intervention group
Group type: COMPARATOR
Intervention: South Asian parents
Number of subjects: 320
Study 26998310 — intervention group
Group type: COMPARATOR
Intervention: East/Southeast Asian parents
Number of subjects: 320
Study 26998310 — intervention group
Group type: COMPARATOR
Intervention: Immigrants to Canada
Number of subjects: 320
Study 26998310 — intervention group
Group type: COMPARATOR
Intervention: Higher education level
Number of subjects: 320
Study 26998355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 grams of plant stanols
Number of subjects: 143
Study 26998355 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 grams of plant stanols
Number of subjects: 143
Study 26998355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 grams of plant stanols with camelina oil
Number of subjects: 143
Study 26998355 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 grams of plant stanols with camelina oil
Number of subjects: 143
Study 26998355 — intervention group
Group type: COMPARATOR
Intervention: Placebo minidrink (no plant stanols or camelina oil)
Number of subjects: 143
Study 26998426 — intervention group
Group type: EXPERIMENTAL
Intervention: CT+G (chemotherapy plus goserelin)
Number of subjects: 0
Study 26998426 — intervention group
Group type: COMPARATOR
Intervention: CT (chemotherapy only)
Number of subjects: 0
Study 26999488 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiangiogenic therapy
Number of subjects: 10
Study 27000099 — intervention group
Group type: EXPERIMENTAL
Intervention: FSA-NPS DI (continuous and sex-specific quartiles)
Number of subjects: 6515
Study 27000099 — intervention group
Group type: EXPERIMENTAL
Intervention: FSA-NPS DI in smokers
Number of subjects: 6515
Study 27000099 — intervention group
Group type: EXPERIMENTAL
Intervention: FSA-NPS DI in physically inactive individuals
Number of subjects: 6515
Study 27000348 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27000446 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + mCIT
Number of subjects: 34
Study 27000446 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 34
Study 27000643 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 178
Study 27000643 — intervention group
Group type: COMPARATOR
Intervention: Control (no NSAIDs)
Number of subjects: 178
Study 27001664 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity training (HIT) program for 9 weeks
Number of subjects: 79
Study 27001822 — intervention group
Group type: EXPERIMENTAL
Intervention: M-EDTA-EtOH lock solution administered once daily for 2 hours for a total of 7 doses.
Number of subjects: 30
Study 27001822 — intervention group
Group type: COMPARATOR
Intervention: CVC removal and reinsertion (control group).
Number of subjects: 30
Study 27001822 — intervention group
Group type: EXPERIMENTAL
Intervention: M-EDTA-EtOH lock solution.
Number of subjects: 30
Study 27002141 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 (S3)
Number of subjects: 94
Study 27002141 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN XT (S-XT)
Number of subjects: 94
Study 27002157 — intervention group
Group type: EXPERIMENTAL
Intervention: eIF2α-P activation
Number of subjects: 0
Study 27002214 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy weight infants (WFL percentile at the fifth to ≤95)
Number of subjects: 1416
Study 27002214 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight infants (WFL percentile >95th)
Number of subjects: 1416
Study 27002214 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy weight infants
Number of subjects: 1416
Study 27002214 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers who were overweight
Number of subjects: 1416
Study 27002421 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2164
Study 27002421 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2164
Study 27002421 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 2164
Study 27002421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2164
Study 27002703 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 65
Study 27002703 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress and positive emotional eating
Number of subjects: 65
Study 27002703 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonia
Number of subjects: 65
Study 27002703 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 65
Study 27003363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus CapeOx (capecitabine 850 mg/m2 bid, day 1-14; oxaliplatin 130 mg/m2, day 1; pazopanib 800 mg, day 1-21)
Number of subjects: 66
Study 27003553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported bowel movements (BMs) per week at baseline: 3.7 (SD 2.9)
Number of subjects: 489
Study 27003553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported spontaneous bowel movements per week at baseline: 1.4 (SD 2.3)
Number of subjects: 489
Study 27003553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported gastrointestinal-related symptoms of at least moderate intensity at baseline: 97%
Number of subjects: 489
Study 27003553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported gastrointestinal-related symptoms of at least moderate intensity at week 24: 82%
Number of subjects: 489
Study 27003553 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement between HCPs and patients on the presence of constipation at baseline: 61%
Number of subjects: 489
Study 27003553 — intervention group
Group type: EXPERIMENTAL
Intervention: Average pain ratings at week 24: HCPs 5.9 vs. patients 6.0
Number of subjects: 489
Study 27003553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who spoke to HCPs about constipation in the past month: 63%
Number of subjects: 489
Study 27003553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients whose HCPs asked about constipation in the past month: 62%
Number of subjects: 489
Study 27003573 — intervention group
Group type: EXPERIMENTAL
Intervention: 23mm valve (N = 77)
Number of subjects: 235
Study 27003573 — intervention group
Group type: EXPERIMENTAL
Intervention: 26mm valve (N = 91)
Number of subjects: 235
Study 27003573 — intervention group
Group type: EXPERIMENTAL
Intervention: 29mm valve (N = 67)
Number of subjects: 235
Study 27003573 — intervention group
Group type: EXPERIMENTAL
Intervention: All valve sizes
Number of subjects: 235
Study 27004234 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid collection for antibody detection
Number of subjects: 0
Study 27004241 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-3 subgroup (72-hour PPI infusion)
Number of subjects: 316
Study 27004241 — intervention group
Group type: COMPARATOR
Intervention: Day-2 subgroup (one day early PPI infusion)
Number of subjects: 316
Study 27004241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic epinephrine-injection monotherapy
Number of subjects: 316
Study 27004241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia < 3.0 g/dL
Number of subjects: 316
Study 27004241 — intervention group
Group type: EXPERIMENTAL
Intervention: Forrest Ia-Ib type
Number of subjects: 316
Study 27004241 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia < 3.5 g/dL
Number of subjects: 316
Study 27004243 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ)
Number of subjects: 26
Study 27004426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 40
Study 27004532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadofosveset trisodium 0.06 mmol/kg
Number of subjects: 28
Study 27004552 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring touch (tactile massage and healing touch)
Number of subjects: 41
Study 27004905 — intervention group
Group type: EXPERIMENTAL
Intervention: TTIP-PRO (tailored telephone intervention delivered by peers)
Number of subjects: 8
Study 27005892 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cell therapy using CD133+ bone marrow-derived stem cells (BMDSCs) in conjunction with hormonal replacement therapy
Number of subjects: 18
Study 27006491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib therapy
Number of subjects: 48
Study 27006492 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL infusion followed by attenuated doses of IL2 administered in an intravenous, continuous decrescendo regimen
Number of subjects: 25
Study 27006492 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL infusion followed by attenuated doses of IL2
Number of subjects: 25
Study 27006728 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg weekly plus methotrexate for 24 weeks, continued for 104 weeks; total exposure 798.1 patient-years.
Number of subjects: 386
Study 27006728 — intervention group
Group type: COMPARATOR
Intervention: Conventional DMARD (hydroxychloroquine or sulfasalazine) plus methotrexate for 24 weeks, followed by treatment modification.
Number of subjects: 386
Study 27006728 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (continued or added) in the treatment regimen after week 24.
Number of subjects: 386
Study 27007958 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin-based drugs (DPP-4 inhibitors and GLP-1 analogues)
Number of subjects: 1499650
Study 27007958 — intervention group
Group type: COMPARATOR
Intervention: Oral antidiabetic-drug combinations
Number of subjects: 1499650
Study 27007959 — intervention group
Group type: COMPARATOR
Intervention: Dengue vaccine efficacy (control group)
Number of subjects: 10363
Study 27008504 — intervention group
Group type: EXPERIMENTAL
Intervention: YouGrabber® system (YouRehab AG, Zurich, Switzerland)
Number of subjects: 15
Study 27008687 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (placebo-controlled)
Number of subjects: 63
Study 27008687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 27008687 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia or sedation
Number of subjects: 63
Study 27008687 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blinded trials
Number of subjects: 63
Study 27008687 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-blinded trials
Number of subjects: 63
Study 27008687 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of study
Number of subjects: 63
Study 27008892 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h oral glucose tolerance test (5 h OGTT)
Number of subjects: 122
Study 27008892 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h AUC insulin and C-peptide
Number of subjects: 122
Study 27008892 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h AUC C-peptide/insulin
Number of subjects: 122
Study 27008892 — intervention group
Group type: COMPARATOR
Intervention: 5 h AUC insulin and C-peptide in lean patients with RH
Number of subjects: 122
Study 27009059 — intervention group
Group type: EXPERIMENTAL
Intervention: Marizomib (MRZ) schedule A at 0.7 mg/m(2) infused over 10 minutes, administered to 32 patients.
Number of subjects: 68
Study 27009059 — intervention group
Group type: EXPERIMENTAL
Intervention: Marizomib (MRZ) schedule B at 0.5 mg/m(2) infused over 2 hours, administered to 36 patients.
Number of subjects: 68
Study 27009059 — intervention group
Group type: EXPERIMENTAL
Intervention: Marizomib (MRZ) overall (both schedules).
Number of subjects: 68
Study 27009059 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to Marizomib.
Number of subjects: 68
Study 27009082 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 12
Study 27009092 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant aromatase inhibitors (AIs)
Number of subjects: 494
Study 27009168 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating desmosine (pDES) in COPD patients
Number of subjects: 1177
Study 27009168 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating desmosine (pDES) in COPD patients with cardiovascular disease
Number of subjects: 1177
Study 27009168 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 1177
Study 27009167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis subjects with previous Pseudomonas aeruginosa infection
Number of subjects: 51
Study 27009167 — intervention group
Group type: COMPARATOR
Intervention: Cystic fibrosis subjects without Pseudomonas aeruginosa
Number of subjects: 51
Study 27009167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis subjects
Number of subjects: 51
Study 27009167 — intervention group
Group type: COMPARATOR
Intervention: Control subjects from a previously reported study
Number of subjects: 51
Study 27009439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan processed wine
Number of subjects: 0
Study 27009547 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid Major Depressive Disorder (MDD)
Number of subjects: 443
Study 27009547 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid Anxiety Disorder (AnxD)
Number of subjects: 443
Study 27009547 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance-Induced Depression (SID)
Number of subjects: 443
Study 27009547 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities (MDD, SID, AnxD)
Number of subjects: 443
Study 27010542 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (single dose 0.25 mg base/kg)
Number of subjects: 819
Study 27011794 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D for six months
Number of subjects: 7
Study 27012243 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD progression (primary endpoint)
Number of subjects: 450
Study 27012243 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of left ventricular hypertrophy or hypertension (secondary outcome)
Number of subjects: 450
Study 27012243 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment of growth (secondary outcome)
Number of subjects: 450
Study 27012243 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological status (secondary outcome)
Number of subjects: 450
Study 27012243 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral status (secondary outcome)
Number of subjects: 450